In clinical trials, more than half of all patients treated with deucravacitinib achieved at least 20% improvement in American College of Rheumatology response criteria.
Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at Week 16 in the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical ...
New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for la ...
The Prostate Cancer Centre, along with Hart, will be hosting its annual men’s health event from 10 a.m. until 4 p.m., ...
ZME Science on MSN
A new type of immunotherapy drug for prostate cancer shows up to 99% drop in cancer biomarkers
Our immune system is great at fighting many types of cancer, but it struggles to see prostate tumors. While new treatments have been game-changers for lung cancer and skin cancer, prostate cancer ...
Investigators sought to determine the effect of “Smart PSA” guidelines on screening behavior and biopsy outcomes among Black men.
It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results